摘要
目的研究布地奈德福莫特罗对哮喘患者血清中CCL28的影响。方法取轻中度急性发作期哮喘患者的静脉血,分离血清后,检测血清中CCL28的含量,对患者进行布地奈德福莫特罗干预,1w后复查血清中的CCL28。结果急性发作期哮喘患者血清中CCL28为(37.58±3.64)ng/mL,布地奈德福莫特罗干预后患者血清CCL28降为(10.37±1.05)ng/mL。结论布地奈德福莫特罗能明显降低CCL28,可能对抑制哮喘急性期嗜酸性细胞炎症起重要作用。
Objective To investigate the effect of budesonide fomoterol on CCL28expression in the serum of asthma patients.Methods Asthma patients in acute exacerbation were taken the venous blood.After the separation of serum,the content of CCL28were tested.The patients received budesonide fomoterol treatment.All the patients received CCL28detection one week later.Results The CCL28level in patients of acute exacerbation was(37.58±3.64)ng/mL.After budesonide fomoterol treatment,the CCL28level in patients was(10.37±1.05)ng/mL.Conclusion Budesonide fomoterol could significantly reduce CCL28level of asthma patients in acute exacerbation,and may play an important role in inhibiting the eosinophilic inflammation in acute asthma.
作者
史莹
周丹阳
谷伟
SHI Ying;ZHOU Dan-yang;GU Wei(Department of Respiratory Medicine, the First Hospital of Nanjing, Nanjing 210006, China)
出处
《中国生化药物杂志》
CAS
2017年第11期147-148,共2页
Chinese Journal of Biochemical Pharmaceutics